Company Overview of Cadila Pharmaceuticals Limited
Cadila Pharmaceuticals Limited operates as a pharmaceutical company worldwide. The company develops branded and generic formulations for humans and animals; active pharmaceutical ingredients; biotechnology products and diagnostic kits; and plant tissue cultures. It also offers contract research and contract manufacturing services. The company offers its products for various therapeutic areas, including cardiovascular, gastrointestinal, analgesics, haematinics, anti-infectives, antibiotics, respiratory, anti diabetics, immunologicals, antipyretics, anthelmintics, anti-hypertensives, anti-inflammatory preparations, antibacterials, vitamins, iron and protein tonics, and ophthalmology. It has a ...
Key Executives for Cadila Pharmaceuticals Limited
Chairman and Managing Director
Compensation as of Fiscal Year 2015.
Cadila Pharmaceuticals Limited Key Developments
MicroCoal Technologies Inc. and Cadila Pharmaceuticals Limited Enter into Joint Venture Agreement for India
Jan 16 15
MicroCoal Technologies Inc. announced that it has signed a definitive investment agreement with an affiliate of Cadila Pharmaceuticals Limited and has entered into a joint venture agreement with Cadila for the Republic of India. Under the terms of the JV Agreement, MicroCoal and Cadila have agreed to form a corporation domiciled in India in which MicroCoal and Cadila will each hold a 50% interest. JVCO is expected to carry on its activities throughout India, and its key functions are planned to include: establishing and operating a testing/demonstration facility for the purpose of demonstrating the cost effectiveness of MicroCoal's technology to companies in the coal mining or coal-based electricity generation industries in India; marketing and promoting MicroCoal's technology throughout India; and developing one or more commercial-scale facilities in India based upon or incorporating MicroCoal's technology. Pursuant the JV Agreement, the parties have agreed to enter into an intellectual property license agreementwhereby MicroCoal will contribute its technology to JVCO by granting JVCO a fully paid up license to, among other things, research and develop and commercialize MicroCoal's intellectual property in India. The license agreement will permit JVCO to establish a testing/demonstration facility in India, utilize the MicroCoal trademark to market the technology in India and develop or sell commercial facilities. Closing of the Investment and the JV Agreement is subject to customary closing conditions, including receipt of any required regulatory approvals.
Cadila Pharmaceuticals (India) Launches Biosimilar Anti-Inflammatory Candidate in India
Dec 10 14
Cadila Pharmaceuticals (India) has launched a biosimilar version of AbbVie's (US) blockbuster medicine Humira (adalimumab). The biosimilar treatment, marketed under the product name Exemptia, has been approved by the Drug Control General for India for the management of inflammatory processes associated with autoimmune diseases; approved indicators include rheumatoid arthritis, psoriatic arthritis, juvenile idiopathic arthritis, and ankylosing spondylitis. Cadila is also seeking, and is likely to secure, approvals for Crohn's disease, psoriasis, and ulcerative colitis. Humira generated global sales worth USD 10.7 billion for AbbVie in 2013, an increase of 15% year on year. That growth trajectory is continuing to climb after the company secured additional indications globally. The anti-inflammatory drug is set to go off-patent in the US in December 2016 followed in April 2018 in the EU; although AbbVie would presumably defend its patent for more recently approved indications. In a statement Cadila said it is readying the biosimilar version for entry into the US market in 2019. At least eight other companies are in the race to launch a competitor medicine to Humira including Amgen (US) ABP 501, which recently reported positive Phase III trial results (seeUnited States: 9 October 2014:). Also in the pipeline is the Oncobiologics/Viropro (US) version of adalimumab known as ONS-3010; phase I clinical trials at the Center for Human Disease Research in Leiden are due to be completed by the end of 2014. Other promising adalimumab biosimilars that are under development include Sandoz's (Switzerland) GB2017 copy, which announced the start of Phase III clinical trials in December 2013. The trial to evaluate the efficacy, safety and immunogenicity of GB2017 regarding Humira in patients with moderate to severe chronic plague-type psoriasis is expected to be completed in June 2015. Cadila Pharmaceutical's copy of the adalimumab drug therapy will be administered as 40 mg subcutaneous injection once every alternate week with the treatment normally lasting six months.
NovaSAID AB Announces Strategic Partnership with Cadila Pharmaceuticals Limited to Develop Innovative Treatments in Inflammation and Pain Management
Jan 10 14
NovaSAID AB and Cadila Pharmaceuticals Ltd. announced a strategic partnership to develop new treatments for inflammation and pain in conditions such as rheumatoid arthritis. The companies will collaborate around preclinical and clinical development of drug candidates that have been developed by NovaSAID and the development will be onducted at Cadila Pharmaceuticals’ facility in Ahmedabad, India. According to the agreement, all revenue generated from the sale and marketing in India, Middle East and Africa of products covered by the agreement will be retained by Cadila and net sales in all other countries will be shared by the two companies. Cadila will bear all costs associated with the program through to Phase II. Many of the medical treatments for inflammation and pain are associated with unwanted side effects such as an increased risk for myocardial infarction and gastric ulcers. NovaSAID’s drug candidates targets an enzyme called microsomal prostaglandin E synthase -1 (mPGES-1), a critically important mediator of inflammation and pain, which theoretically should reduce the risk for side effects. The collaboration with Cadila will provide the resources to take this program into clinical development and further towards the market.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|